Boost for Basilea as isavuconazole meets Phase III endpoint
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica and global co-development partner Astellas have reached what they see as a critical milestone in the development of their broad-spectrum antifungal isavuconazole, which has demonstrated non-inferiority to voriconazole in a Phase III trial for invasive aspergillosis.